Key Laboratory of Modern Chinese Medicines, China Pharmaceutical University, Nanjing, PR China.
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China.
Pharm Dev Technol. 2021 Jun;26(5):549-558. doi: 10.1080/10837450.2021.1899203. Epub 2021 Mar 18.
Solidification of self-microemulsifying drug delivery systems (SMEDDS) is one of the major trends to promote the transformation of self-microemulsion technology into industrialization. Here, a preliminary curcumin SMEDDS formulation was constructed to improve the druggability of curcumin, through the determination of equilibrium solubility determination, self-emulsifying grading assessment, and pseudo-ternary phase diagrams drafting. Furthermore, the optimal curcumin SMEDDS formulation consisted of 10% Ethyl oleate, 57.82% Cremophor RH 40, and 32.18% Transcutol P was obtained by the simplex lattice design. Besides, curcumin solid self-microemulsifying drug delivery system (S-SMEDDS) was developed by the extrusion and spheronization process to achieve the solidification of SMEDDS. The formulation of curcumin S-SMEDDS pellets was screened by the single factor experiment and the process parameters were investigated using the orthogonal optimization method. Subsequently, curcumin S-SMEDDS pellets were evaluated by apparent morphology characterization, redispersibility study, drug release behavior, and pharmacokinetic evaluation. Results from the pharmacokinetic study in rabbits showed that the AUC of the curcumin S-SMEDDS pellets and curcumin suspension were 5.91 ± 0.28 µg/mL·h and 2.05 ± 0.04 µg/mL·h, while the relative bioavailability was 289.30%. These studies demonstrated that S-SMEDDS pellets can be a promising strategy for curcumin industrialized outputs.
自微乳药物传递系统(SMEDDS)的固化是促进自微乳技术向工业化转化的主要趋势之一。在这里,构建了初步的姜黄素 SMEDDS 配方,通过测定平衡溶解度、自乳化分级评估和拟三元相图起草来提高姜黄素的可成药性。此外,通过单纯形格子设计,获得了由 10%油酸乙酯、57.82%吐温 RH40 和 32.18% Transcutol P 组成的最佳姜黄素 SMEDDS 配方。此外,通过挤出和滚圆工艺开发了姜黄素固体制剂自微乳药物传递系统(S-SMEDDS),以实现 SMEDDS 的固化。通过单因素实验筛选姜黄素 S-SMEDDS 丸剂的配方,并采用正交优化方法考察工艺参数。随后,通过外观形态特征、再分散性研究、药物释放行为和药代动力学评价对姜黄素 S-SMEDDS 丸剂进行评价。在兔体内药代动力学研究结果表明,姜黄素 S-SMEDDS 丸剂和姜黄素混悬液的 AUC 分别为 5.91±0.28μg/mL·h 和 2.05±0.04μg/mL·h,相对生物利用度为 289.30%。这些研究表明,S-SMEDDS 丸剂可能是姜黄素工业化生产的一种有前途的策略。